iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging and computed tomography. ProFound Suite offers 360-degree solutions for cancer detection, density assessment, and personalized risk evaluation, all based on a 2D or 3D mammogram’s collection of images. ProFound Density Assessment standardizes and simplifies breast density reporting, algorithmically examining a woman’s breast anatomy from the mammogram image.
BörsenkürzelICAD
Name des UnternehmensICAD Inc
IPO-datumDec 13, 1984
CEOMs. Dana R. Brown
Anzahl der mitarbeiter66
WertpapierartOrdinary Share
GeschäftsjahresendeDec 13
Addresse98 Spit Brook Rd Ste 100
StadtNASHUA
BörseEuronext Paris
LandUnited States of America
Postleitzahl03062-5737
Telefon16038825200
Websitehttps://www.icadmed.com/
BörsenkürzelICAD
IPO-datumDec 13, 1984
CEOMs. Dana R. Brown
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten